Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $153.1 million.

  • Inhibrx Biosciences' Cash & Equivalents fell 2201.98% to $153.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.1 million, marking a year-over-year decrease of 2201.98%. This contributed to the annual value of $152.6 million for FY2024, which is 4509.43% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Cash & Equivalents is $153.1 million, which was down 2201.98% from $186.6 million recorded in Q2 2025.
  • Inhibrx Biosciences' Cash & Equivalents' 5-year high stood at $277.9 million during Q4 2023, with a 5-year trough of $152.6 million in Q4 2024.
  • For the 3-year period, Inhibrx Biosciences' Cash & Equivalents averaged around $201.4 million, with its median value being $196.3 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 4509.43% in 2024, then crashed by 1776.11% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Cash & Equivalents (Quarter) stood at $277.9 million in 2023, then plummeted by 45.09% to $152.6 million in 2024, then grew by 0.33% to $153.1 million in 2025.
  • Its Cash & Equivalents was $153.1 million in Q3 2025, compared to $186.6 million in Q2 2025 and $216.5 million in Q1 2025.